Smith RJ, Okano JT, Kahn JS, Bodine EN, Blower S. Evolutionary dynamics of complex networks of HIV drug-resistant strains: the case of San Francisco

Center for Biomedical Modeling, Semel Institute of Neuroscience & Human Behavior, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90024, USA.
Science (Impact Factor: 33.61). 02/2010; 327(5966):697-701. DOI: 10.1126/science.1180556
Source: PubMed


Over the past two decades, HIV resistance to antiretroviral drugs (ARVs) has risen to high levels in the wealthier countries of the world, which are able to afford widespread treatment. We have gained insights into the evolution and transmission dynamics of ARV resistance by designing a biologically complex multistrain network model. With this model, we traced the evolutionary history of ARV resistance in San Francisco and predict its future dynamics. By using classification and regression trees, we identified the key immunologic, virologic, and treatment factors that increase ARV resistance. Our modeling shows that 60% of the currently circulating ARV-resistant strains in San Francisco are capable of causing self-sustaining epidemics, because each individual infected with one of these strains can cause, on average, more than one new resistant infection. It is possible that a new wave of ARV-resistant strains that pose a substantial threat to global public health is emerging.

Download full-text


Available from: Sally Blower, Feb 28, 2014
1 Follower
42 Reads
  • Source
    • "The introduction of highly active antiretroviral therapy (HAART) has significantly decreased morbidity and mortality among HIV-1-infected patients with access to these drugs. However, the development of drug resistance and issues related to drug tolerability and compliance often pose a considerable challenge to current therapies [4-8]. These concerns, together with recent reports of failure in clinical trials of HIV vaccines and several microbicides, reinforce the critical need to identify new targets for the development of novel classes of anti-HIV-1 drugs. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Previously, we reported the conversion of the 12-mer linear and cell-impermeable peptide CAI to a cell-penetrating peptide NYAD-1 by using an i,i + 4 hydrocarbon stapling technique and confirmed its binding to the C-terminal domain (CTD) of the HIV-1 capsid (CA) protein with an improved affinity (Kd ~ 1 muM) compared to CAI (Kd ~ 15 muM). NYAD-1 disrupts the formation of both immature- and mature-like virus particles in in vitro and cell-based assembly assays. In addition, it displays potent anti-HIV-1 activity in cell culture against a range of laboratory-adapted and primary HIV-1 isolates. In this report, we expanded the study to i,i + 7 hydrocarbon-stapled peptides to delineate their mechanism of action and antiviral activity. We identified three potent inhibitors, NYAD-36, -66 and -67, which showed strong binding to CA in NMR and isothermal titration calorimetry (ITC) studies and disrupted the formation of mature-like particles. They showed typical alpha-helical structures and penetrated cells; however, the cell penetration was not as efficient as observed with the i,i + 4 peptides. Unlike NYAD-1, the i,i + 7 peptides did not have any effect on virus release; however, they impaired Gag precursor processing. HIV-1 particles produced in the presence of these peptides displayed impaired infectivity. Consistent with an effect on virus entry, selection for viral resistance led to the emergence of two mutations in the gp120 subunit of the viral envelope (Env) glycoprotein, V120Q and A327P, located in the conserved region 1 (C1) and the base of the V3 loop, respectively. The i,i + 7 stapled peptides derived from CAI unexpectedly target both CA and the V3 loop of gp120. This dual-targeted activity is dependent on their ability to penetrate cells as well as their net charge. This mechanistic revelation will be useful in further modifying these peptides as potent anti-HIV-1 agents.
    Retrovirology 11/2013; 10(1):136. DOI:10.1186/1742-4690-10-136 · 4.19 Impact Factor
  • Source
    • "Fourth, an analysis of RC does not account for the emergence and transmission of drug-resistant strains. When resistance emerges, multiple Rc's need to be evaluated in order to determine if elimination is (theoretically) possible [12], [13], [17] In addition, it needs to be understood the conditions that reduce RC to below one (e.g., the degree of viral suppression that reduces infectivity to 96%) would need to be continuously maintained until all of the treated individuals have died. Incidence would increase if the necessary conditions were not continuously maintained. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In South Africa (SA) universal access to treatment for HIV-infected individuals in need has yet to be achieved. Currently ∼1 million receive treatment, but an additional 1.6 million are in need. It is being debated whether to use a universal 'test and treat' (T&T) strategy to try to eliminate HIV in SA; treatment reduces infectivity and hence transmission. Under a T&T strategy all HIV-infected individuals would receive treatment whether in need or not. This would require treating 5 million individuals almost immediately and providing treatment for several decades. We use a validated mathematical model to predict impact and costs of: (i) a universal T&T strategy and (ii) achieving universal access to treatment. Using modeling the WHO has predicted a universal T&T strategy in SA would eliminate HIV within a decade, and (after 40 years) cost ∼$10 billion less than achieving universal access. In contrast, we predict a universal T&T strategy in SA could eliminate HIV, but take 40 years and cost ∼$12 billion more than achieving universal access. We determine the difference in predictions is because the WHO has under-estimated survival time on treatment and ignored the risk of resistance. We predict, after 20 years, ∼2 million individuals would need second-line regimens if a universal T&T strategy is implemented versus ∼1.5 million if universal access is achieved. Costs need to be realistically estimated and multiple evaluation criteria used to compare 'treatment as prevention' with other prevention strategies. Before implementing a universal T&T strategy, which may not be sustainable, we recommend striving to achieve universal access to treatment as quickly as possible. We predict achieving universal access to treatment would be a very effective 'treatment as prevention' approach and bring the HIV epidemic in SA close to elimination, preventing ∼4 million infections after 20 years and ∼11 million after 40 years.
    PLoS ONE 09/2012; 7(9):e41212. DOI:10.1371/journal.pone.0041212 · 3.23 Impact Factor
  • Source
    • "Other authors have raised other issues including the potential importance of adherence, sexual disinhibition, the lack of capacity and overwhelming costs of expanding access to ART [150], as well as the importance of the acute phase of HIV infection [151] [152]. Although modelling is important, programme data, research studies and field trials would need to examine the key thresholds for programme performance raised in the supporting information of the recent Lancet paper [31] and in subsequent articles by the modelling community [133] [134] [139] [140] [141] [142] [143] [150]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: After 30 years we are still struggling to address a devastating HIV pandemic in which over 25 million people have died. In 2010, an estimated 34 million people were living with HIV, around 70% of whom live in sub-Saharan Africa. Furthermore, in 2009 there were an estimated 1.2 million new HIV-associated TB cases, and tuberculosis (TB) accounted for 24% of HIV-related deaths. By the end of 2010, 6.6 million people were taking antiretroviral therapy (ART), around 42% of those in need as defined by the 2010 World Health Organization (WHO) guidelines. Despite this achievement, around 9 million people were eligible and still in need of treatment, and new infections (approximately 2.6 million in 2010 alone) continue to add to the future caseload. This combined with the international fiscal crisis has led to a growing concern regarding weakening of the international commitment to universal access and delivery of the Millennium Development Goals by 2015. The recently launched UNAIDS/WHO Treatment 2.0 platform calls for accelerated simplification of ART, in line with a public health approach, to achieve and sustain universal access to ART, including maximizing the HIV and TB preventive benefit of ART by treating people earlier, in line with WHO 2010 normative guidance. The potential individual and public health prevention benefits of using treatment in the prevention of HIV and TB enhance the value of the universal access pledge from a life-saving initiative, to a strategic investment aimed at ending the HIV epidemic. This review analyzes the gaps and summarizes the evidence regarding ART in the prevention of HIV and TB.
    Current HIV Research 08/2011; 9(6):355-366. DOI:10.2174/157016211798038551 · 1.76 Impact Factor
Show more